Diabetes mellitus, HBA1C, and in vivo Alzheimer's disease pathologies: Neuroimaging / Optimal neuroimaging measures for tracking disease progression.

MLA

Han, Dongkyun, et al. “Diabetes Mellitus, HBA1C, and in Vivo Alzheimer’s Disease Pathologies: Neuroimaging / Optimal Neuroimaging Measures for Tracking Disease Progression.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, vol. 16, no. 11, Dec. 2020, p. 1. EBSCOhost, https://doi.org/10.1002/alz.044752.

APA

Han, D., Byun, M. S., Yi, D., Lee, J. H., Byeon, G., Joung, H., Moon, S. W., Sohn, B. K., Lee, J., Kim, Y. K., Lee, Y., Sohn, C., & Lee, D. Y. (2020). Diabetes mellitus, HBA1C, and in vivo Alzheimer’s disease pathologies: Neuroimaging / Optimal neuroimaging measures for tracking disease progression. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 16(11), 1. https://doi.org/10.1002/alz.044752

Chicago

Han, Dongkyun, Min Soo Byun, Dahyun Yi, Jun Ho Lee, Gihwan Byeon, Haejung Joung, Seok Woo Moon, et al. 2020. “Diabetes Mellitus, HBA1C, and in Vivo Alzheimer’s Disease Pathologies: Neuroimaging / Optimal Neuroimaging Measures for Tracking Disease Progression.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 16 (11): 1. doi:10.1002/alz.044752.